Tue, 09/28/2021 - 11:46
Eli Lilly is conducting a voluntary nationwide recall of one lot (D239382D, Expiration: April 2022) of Glucagon Emergency Kit for Low Blood Sugar to the patient level because of a product complaint reporting that the vial of Glucagon was in liquid form instead of the powder form. Lilly’s investigation indicates that the liquid in this Glucagon vial could be related to the manufacturing process. The use of the liquid form of this product may fail to treat severe low blood sugar due to loss of potency.
The product is packaged in a kit containing 1mg of freeze-dried (lyophilized) product in a 3 mL vial and a pre-filled diluent syringe. The affected Glucagon Emergency Kit lot is D239382D and the expiration date is April 2022 (label expiry date: 04 2022). The lot number can be found on the label of the kit as well as the vial.
What do I need to know?
• You can find general information about this recall on the FDA website:
• Express Scripts will mail letters to any patient who was dispensed any lot of Glucagon Emergency Kit within the last 120 days.
• Patients who have received Glucagon Emergency Kit should check the lot number on the package to determine whether they are impacted.
• Patients who are in possession of Glucagon Emergency Kit lot D239382D should contact The Lilly Answers Center at 1-800-LILLYRX (1-800-545-5979) for return instructions for the product (hours of operation are Monday- Friday, 9AM – 7PM EST) and should contact their health care provider for guidance.
• If you choose to stay on this therapy but need to obtain a fresh supply and it is not time for your next refill, please call us at the toll free number on your prescription bottle to request an early refill. Your order will be filled with medication that is not part of any existing recall.
• Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.
You can also report adverse events or quality problems related to the use of the drug to the FDA’s MedWatch Adverse Events Reporting Program. Call 800.FDA.1088 or go to https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
Last updated: Tue, 09/28/2021 - 12:05